Alexion Pharmaceuticals Inc. (New H...

Alexion Pharmaceuticals Inc. (New Haven, CT) Phase 2b Cardiopulmonary Bypass pexelizumab trial data showed that administration of the thought drug was associated with a reduction in the composite incidence of death or myocardial infarction. In the double-blind, randomized, placebo-controlled trial, 914 exposes at 65 U.S. medical center were stratified into brace groups. One group underwent solely CABS with CPB and the other CABG with concomitant valve surgery during CPB Approximately 90% of subdues were in the CABG-only cluster Subjects were treated with placebo, pexelizumab 20 mg/kg